In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 EMAIL TO FRIEND     |      PRINTER FRIENDLY     |    
          advertisement

Drug Combo Keeps Kidney Artery-Vein Grafts Viable

May 20 (HealthDay News) -- A combination of aspirin and the anti-clotting drug dipyridamole reduces blockages and extends the useful life of new artery-vein access grafts used for kidney dialysis, new research has found.

When arteriovenous (AV) grafts fail, it is often due to stenosis -- a narrowing of blood vessels -- at the graft site, and subsequent clotting. If the AV graft is blocked, it can't be used for dialysis, and this is a major cause of declining health in dialysis patients, according to background information in a U.S. National Institute of Diabetes and Digestive and Kidney Diseases news release about the study.

In the study from the Dialysis Access Consortium, 649 patients with new AV grafts at 13 sites in the United States were randomly assigned to the combination treatment or placebo. The researchers found that the combination treatment decreased the rate of loss of primary unassisted graft patency (the useful life of a graft before it's blocked for the first time) by 18 percent and the rate of developing significant stenosis by 28 percent.

"Our trial results show that we now have a drug therapy that significantly prolongs the viability of AV grafts. This is an important step forward as we proceed to develop therapies to improve dialysis patients' quality of life," lead author Dr. Bradley S. Dixon, of the University of Iowa College of Medicine in Iowa City, said in the news release.

The study, which was supported by Boehringer Ingelheim Pharmaceuticals, Inc., appears in the May 21 issue of the New England Journal of Medicine.

"This drug combination provides a modest but important new therapy to keep AV grafts in good working order so patients can get the dialysis they need. But clearly, more research is needed to extend the useful life of AV grafts," Dr. Griffin P. Rodgers, director of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases, said in the news release. The institute also supported the study.

Kidney failure affects more than half a million people in the United States, and 70 percent of them are on dialysis, according to background information in the news release.


SOURCE: U.S. National Institute of Diabetes and Digestive and Kidney Diseases, news release, May 20, 2009

advertisement

Advice from Dr. Nancy Snyderman

Dr. Nancy Snyderman

Helpful tips and information on weight loss

Get answers from an expert
advertisement

YourTotalHealth      

Home  |  Health Centers  |  Health A-Z  |  Staying Healthy  |  Diet & Fitness  |  Woman & Family  |  Pregnancy  |  Community  |  

also on iVillage: Pregnancy & Parenting  |  Beauty & Style  |  Home & Garden  |  Food  |  Weddings  |  Love  |  Entertainment  |  NeverSayDiet

Terms of Service  |  Privacy Policy  |  Site Map  |  Newsletters  |  Feedback

Copyright (c) 2000-2009 iVillage Inc. All rights reserved. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.